Trispecific Abs

Affimed’s Trispecific Abs platform could pave the way for cancer
products with substantially widened therapeutic window.

 
 
     
 
  Trispecific Antibodies  
   
 

Affimed’s Trispecific Abs platform could pave the way for cancer products with a substantially widened therapeutic window. Through Affimed’s proprietary tetravalent domain structure, it has the ability to generate antibodies that exhibit three different binding sites. Such structures are normally challenging to make, but Affimed has succeeded in generating such molecules and has found that they have all the features to be used as drug candidates, such as manufacturability and stability. Affimed’s initial work is aimed at targeting two different tumor targets, and with a third functionality, engaging T-cells or NK-cells to exert a cytotoxic effect. Targeting two tumor targets allows for greater selectivity for cancer cells, sparing healthy tissue and resulting in a wider therapeutic window, or dose range within which the drug can be effective in eradicating cancer cells without causing unacceptable levels of side effects.


   
 
 
Poster
 
     
 
  ASH 2016 – Trispecific Abs              
 
 
 
 
  Impressum Disclaimer